Introduction
============

Shock-related hyperglycemia impairs mitochondrial function and integrity \[[@B1]\], ultimately leading to apoptosis and organ failure \[[@B1],[@B2]\]. Imeglimin is a new anti-diabetic drug with anti-hyperglycemic and anti-apoptotic properties \[[@B3]\]. Therefore we investigated its effects in hyperglycemic mice with septic shock.

Methods
=======

Immediately after cecal ligation and puncture, mice randomly received s.c. vehicle (*n*= 9) or imeglimin (*n*= 10; 100 μg/g). Fifteen hours later animals were anesthetized, mechanically ventilated and instrumented for a consecutive 6-hour observation period. After a second imeglimin bolus, colloid fluid resuscitation and continuous i.v. noradrenaline were titrated to maintain normotensive and hyperdynamic hemodynamics. Then 2 mg/g/hour glucose was infused to induce hyperglycemia. Glucose oxidation and gluconeogenesis were derived from blood ^13^C~6~-glucose and mixed expiratory ^13^CO~2~/^12^CO~2~isotope enrichment during continuous isotope infusion. Liver mitochondrial activity was assessed using high-resolution respirometry \[[@B4],[@B5]\], Bax, HO-1 and NF-κB expression by immunoblotting and EMSA. All data are median (quartiles).

Results
=======

Imeglimin decreased blood glucose levels (165 (153; 180) vs. 192 (184; 221) mg/dl, *P*= 0.007) by increasing whole body glucose oxidation (55 (52; 57) vs. 51 (49; 55)% of infused isotope, *P*= 0.085), which coincided with partial restoration of gluconeogenesis (0.38 (0.34; 0.41) vs. 0.31 (0.27; 0.33) mg/g/hour, *P*= 0.032), liver mitochondrial activity (oxidative phosphorylation (136 (134; 160) vs. 116 (97; 122) pmol O~2~/second/mg tissue, *P*= 0.003); maximal oxidative capacity (166 (154; 174) vs. 147 (130; 159) pmol O~2~/second/mg tissue, *P*= 0.064). Imeglimin increased liver HO-1, reduced liver Bax expression and attenuated NF-κB activation (all *P*\< 0.001).

Conclusion
==========

Imeglimin improved whole body glucose utilization and gluconeogenesis, a well-established marker of liver metabolic capacity \[[@B4],[@B5]\], and attenuated organ injury, at least in part due to inhibition of the mitochondrial apoptosis pathway.
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